To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Healthcare Professional Resources

General
Locally advanced, unresectable, stage III NSCLC
ES-SCLC
Locally advanced or metastatic BTC
uHCC
Resectable MIBC
GC/GEJC (Stage II to IVA)

IMFINZI Product Monograph

Complete details on IMFINZI’s properties, indications, dosing, contraindications, warnings, adverse events, and clinical pharmacology.

Download

PACIFIC 5-Year Updated Exploratory OS Analysis Publication

IMFINZI's 5-year updated exploratory OS data in Stage III, unresectable NSCLC patients who have not progressed post-CRT.

Spigel DR, Faivre-Finn C, et al. Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12): 1301-1311.

Download

PACIFIC OS Data Summary

An overview of the primary and 5-year updated exploratory OS data.

Download

Dosing Guide

A guide for IMFINZI’s recommended dosage, dosage adjustments, and administration.

Download

Immune-Mediated Adverse Reactions (imARs) Handbook

A guide for recognizing and managing imARs associated with IMFINZI.

Download

CASPIAN 3-Year Updated OS
Analysis Publication

IMFINZI 's 3-year updated OS data in ES-SCLC patients.

Paz-Ares L, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022; 7(2):100408.

Download

CASPIAN OS Data Summary

An overview of the CASPIAN primary and 3-year OS data.

Download

Dosing Guide

A guide for IMFINZI’s recommended dosage, dosage adjustments, and administration.

Download

Immune-Mediated Adverse Reactions (imARs) Handbook

A guide for recognizing and managing imARs associated with IMFINZI.

Download

TOPAZ-1 Trial Paper

Oh DY, He Ar, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):1-11. DOI: 10.1056/EVIDoa2200015.
Reprint of the pivotal TOPAZ-1 trial overall survival results, as published in NEJM Evidence.

Download

Dosing Guide

Provides information on the recommended dosing, preparation and administration of IMFINZI.

Download

Five-year HIMALAYA Trial Paper

Rimassa L, Chan SL, Sangro B, et al. Five-year OS and survival by tumour response with tremelimumab plus durvalumab from the HIMALAYA study in unresectable HCC. J Hepatol. 2025;S0168-8278(25)00226-0. doi: 10.1016/j.jhep.2025.03.033.

Reprint of the 5-Year HIMALAYA trial results, as published in Journal of Hepatology.

Download

Healthcare Professional Resources

IMFINZI Product Monograph

PACIFIC 5-Year Updated Exploratory OS Analysis Publication

PACIFIC OS Data Summary

Dosing Guide

Immune-Mediated Adverse Reactions (imARs) Handbook

CASPIAN 3-Year Updated OS
Analysis Publication

CASPIAN OS Data Summary

Dosing Guide

Immune-Mediated Adverse Reactions (imARs) Handbook

TOPAZ-1 Trial Paper

Dosing Guide

Five-year HIMALAYA Trial Paper

Dosing Guide

IMFINZI HCP Dose Card — Resectable MIBC

IMFINZI Treatment Modification Table — resectable MIBC

IMFINZI NIAGARA HCP Leave-Behind

IMFINZI MATTERHORN— Clinical Overview

IMFINZI AE & Dosing Guide